All the news Showing 10 of 81 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Older people respond equally well to telaprevir triple therapy for hepatitis C Liz Highleyman / 24 October 2013 Interferon-based therapy with telaprevir (Incivo or Incivek) produced a similar cure rate with no notable increase in side-effects or treatment discontinuations for genotype 1 chronic hepatitis C patients over the age of 60, ... Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Simeprevir with interferon effective in genotype 4 HCV infection and for HIV/HCV co-infected people with genotype 1 hepatitis C Liz Highleyman / 21 October 2013 Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ... New drugs will bring revolution in hepatitis C treatment Liz Highleyman / 19 October 2013 The advent of direct-acting antiviral agents can rightly be described as a revolution in treatment for chronic hepatitis C, but potential challenges remain – including drug interactions and cost, Heiner Wedemeyer told participants ... Drug interactions may compromise response to boceprevir and telaprevir Liz Highleyman / 17 June 2013 Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C virus ... Interferon-free simeprevir + sofosbuvir suppresses hepatitis C with or without ribavirin Liz Highleyman / 17 June 2013 An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment sustained response for most prior null responders with genotype 1 hepatitis C in ... Simeprevir boosts response to interferon-based hepatitis C therapy for prior relapsers Liz Highleyman / 03 June 2013 Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after three months, according to ... Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common Liz Highleyman / 17 May 2013 Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at ... ACH-3102 and sovaprevir show potent activity, high barrier to resistance in early studies Keith Alcorn / 14 May 2013 Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented ... Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... ← Prev1...34567...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive